TY - JOUR
T1 - Controversies in Systemic Lupus Erythematosus
T2 - Are We Treating Our Patients Adequately?
AU - Porta, Sabrina Valeria
AU - Ugarte-Gil, Manuel F.
AU - Garciá-De La Torre, Ignacio
AU - Bonfá, Eloísa
AU - Gómez-Puerta, José A.
AU - Arnaud, Laurent
AU - Cardiel, Mario H.
AU - Alarcón, Graciela S.
AU - Pons-Estel, Bernardo A.
AU - Pons-Estel, Guillermo
N1 - Publisher Copyright:
© Wolters Kluwer Health, Inc. All rights reserved.
PY - 2022/3/1
Y1 - 2022/3/1
N2 - Systemic lupus erythematosus (SLE) is characterized by great clinical heterogeneity. The objectives of its management are to make a timely diagnosis and to initiate treatment as promptly as possible so organ damage can be avoided while at the same time exposure to potentially toxic drugs is minimized so that its overall course and outcome improve. In reviewing the current literature, it became quite clear that there are specific topics in which controversies do exist. These include how to treat patients with incomplete lupus erythematosus, the real possibility of abandoning altogether the use of oral glucocorticoids, and the pros and cons of the use of cyclophosphamide and mycophenolate mofetil for the induction treatment of lupus nephritis. Herein we discuss different points of view regarding these still unresolved issues; these comments represent a debate that took place during the PANLAR Virtual Congress (Pan American League of Associations for Rheumatology) and that was organized by the PANLAR Lupus study group, GLADEL (Grupo Latino Americano De Estudio del Lupus) on September 19, 2020.
AB - Systemic lupus erythematosus (SLE) is characterized by great clinical heterogeneity. The objectives of its management are to make a timely diagnosis and to initiate treatment as promptly as possible so organ damage can be avoided while at the same time exposure to potentially toxic drugs is minimized so that its overall course and outcome improve. In reviewing the current literature, it became quite clear that there are specific topics in which controversies do exist. These include how to treat patients with incomplete lupus erythematosus, the real possibility of abandoning altogether the use of oral glucocorticoids, and the pros and cons of the use of cyclophosphamide and mycophenolate mofetil for the induction treatment of lupus nephritis. Herein we discuss different points of view regarding these still unresolved issues; these comments represent a debate that took place during the PANLAR Virtual Congress (Pan American League of Associations for Rheumatology) and that was organized by the PANLAR Lupus study group, GLADEL (Grupo Latino Americano De Estudio del Lupus) on September 19, 2020.
KW - cyclophosphamide
KW - glucocorticoids
KW - incomplete lupus
KW - lupus nephritis
KW - mycophenolate
KW - systemic lupus erythematosus
KW - treatment
UR - http://www.scopus.com/inward/record.url?scp=85125016501&partnerID=8YFLogxK
U2 - 10.1097/RHU.0000000000001803
DO - 10.1097/RHU.0000000000001803
M3 - Artículo
C2 - 34897194
AN - SCOPUS:85125016501
SN - 1076-1608
VL - 28
SP - E651-E658
JO - Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases
JF - Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases
IS - 2
ER -